Third Arc Bio Selects First Lead Candidate Upon 2025 Amended Strategic License Deal With Adagene
Adagene Inc. ("Adagene") (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies today announced that Third Arc Bio,
Adagene and a partner company picked their first main drug to work on together under a new deal. When companies move forward with real drug choices, it shows they believe in the science and have a plan.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.